

Dennis Vriens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/364974/publications.pdf>

Version: 2024-02-01

51
papers

1,144
citations

471509

17
h-index

395702

33
g-index

52
all docs

52
docs citations

52
times ranked

1798
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring and Predicting Response to Therapy with ¹⁸ F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	5.0	197
2	Methodological considerations in quantification of oncological FDG PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1408-1425.	6.4	108
3	The role of [¹⁸ F]â€²fluoroâ€²deoxyâ€²glucoseâ€²positron emission tomography in thyroid nodules with indeterminate fineâ€²needle aspiration biopsy. <i>Cancer</i> , 2011, 117, 4582-4594.	4.1	79
4	A Curve-Fitting Approach to Estimate the Arterial Plasma Input Function for the Assessment of Glucose Metabolic Rate and Response to Treatment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1933-1939.	5.0	68
5	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on ¹⁸ F-FDG PET Imaging of Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1692-1698.	5.0	67
6	Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic Approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3263-3274.	3.6	47
7	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2037-2047.	6.4	45
8	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. <i>Endocrine Reviews</i> , 2018, 39, 154-191.	20.1	45
9	Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A≫G Carriers. <i>JIMD Reports</i> , 2015, 24, 69-81.	1.5	39
10	Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e725-e731.	0.8	35
11	Serum FGF21 levels in adult m.3243A≫G carriers. <i>Neurology</i> , 2014, 83, 125-133.	1.1	33
12	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric ¹⁸ F-FDG PET Images in Nonâ€²Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1033-1039.	5.0	31
13	Semiquantitative ¹²³ I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. <i>Journal of Nuclear Medicine</i> , 2015, 56, 839-846.	5.0	30
14	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPAâ€²Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	5.0	29
15	[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1970-1984.	6.4	22
16	Metabolic Subtyping of Pheochromocytoma and Paraganglioma by ¹⁸ F-FDG Pharmacokinetics Using Dynamic PET/CT Scanning. <i>Journal of Nuclear Medicine</i> , 2019, 60, 745-751.	5.0	21
17	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2174-2188.	6.4	19
18	18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. <i>Skeletal Radiology</i> , 2019, 48, 1735-1746.	2.0	18

#	ARTICLE	IF	CITATIONS
19	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012, 12, 324-335.	2.8	17
20	Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1527-1537.	6.4	17
21	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 550-557.	1.1	16
22	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. <i>Clinical Colorectal Cancer</i> , 2011, 10, E1-E5.	2.3	16
23	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic ¹⁸ F Fluorodeoxyglucose PET. <i>Radiology</i> , 2017, 283, 547-559.	7.3	16
24	⁸⁹ Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1523-1530.	5.0	15
25	Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[¹⁸ F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2980-e2994.	3.6	14
26	Adding the temporal domain to PET radiomic features. <i>PLoS ONE</i> , 2020, 15, e0239438.	2.5	12
27	Chronic temporomandibular joint pain: two cases of osteoid osteoma and a review of the literature. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2017, 46, 1130-1137.	1.5	10
28	The influence of SPECT reconstruction algorithms on image quality and diagnostic accuracy in phantom measurements and ^{99m} Tc-sestamibi parathyroid scintigraphy. <i>Nuclear Medicine Communications</i> , 2014, 35, 64-72.	1.1	9
29	Nuclear medicine radiomics in precision medicine: why we can't do without artificial intelligence. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 278-290.	0.7	9
30	Clinical Pharmacology of Radiotheranostics in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 260-274.	4.7	9
31	FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3452-3469.	6.4	9
32	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. <i>Endocrine</i> , 2016, 54, 642-647.	2.3	8
33	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma. , 2008, , .		7
34	The Influence of the Exclusion of Central Necrosis on [¹⁸ F]FDG PET Radiomic Analysis. <i>Diagnostics</i> , 2021, 11, 1296.	2.6	6
35	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 676-691.	0.7	5
36	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. Endocrine Connections, 2022, 11, .	1.9	4
38	Anakinra Injection Site Reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-493.	1.3	3
39	Hardware Failure. Clinical Nuclear Medicine, 2010, 35, 430-433.	1.3	1
40	F-18 FDG PET/CT as a Crucial Guide Toward Optimal Treatment Planning in a Case of Postirradiation Sarcoma 10 Years After Primary Bone Lymphoma of the Pelvis. Clinical Nuclear Medicine, 2011, 36, 565-567.	1.3	1
41	Shortened Dynamic ¹⁸ F-FDG PET. Journal of Nuclear Medicine, 2011, 52, 1330.1-1330.	5.0	1
42	Considerations on bone volume normalization in quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1351-1352.	6.4	1
43	Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?. Diagnostics, 2021, 11, 553.	2.6	1
44	EP-1851: Quantitative assessment of glucose metabolic rate within NSCLC histologies using dynamic 18F-FDG PET. Radiotherapy and Oncology, 2016, 119, S871.	0.6	0
45	PO-0919: Optimal respiratory gated FDG-PET for characterizing intra-tumour heterogeneity in lung cancer. Radiotherapy and Oncology, 2016, 119, S445.	0.6	0
46	PV-0372: Histology-specific quantitative mapping and targeting of glucose and glutamine metabolism in NSCLC. Radiotherapy and Oncology, 2017, 123, S200-S201.	0.6	0
47	Human Terrain System (United States): Critique. , 2015, , 392-399.		0
48	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
49	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
50	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
51	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0